The World Health Organization warned that artificial sweeteners, used to replace sugar in a vast range of products, do not help in losing weight and can have serious health effects.
According to the United Nations health agency, a systematic review of available evidence "suggests that use of non-sugar sweeteners (NSS) does not confer any long-term benefit in reducing body fat in adults or children.
In addition, results from the review suggest that the long-term use of NSS could increase the risk of type 2 diabetes, cardiovascular diseases, and mortality in adults.
The WHO's director for nutrition and food safety, Francesco Branca, stressed that replacing ordinary sugar with artificial sweeteners "does not help with weight control in the long term".
He added that NSS are not essential dietary factors and have no nutritional value.
The WHO said its new recommendation applied to everyone except individuals with pre-existing diabetes.
It includes all synthetic and naturally occurring or modified sweeteners not classified as sugars found in manufactured foods and beverages or sold on their own to be added to products by consumers.
Among the most widely used sweeteners are acesulfame K, aspartame, advantame, cyclamates, neotame, saccharin, sucralose, stevia, and stevia derivatives, it said.


Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative
Oil Prices Rise as Ukraine Targets Russian Energy Infrastructure
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry
Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook 



